

## ELUCIREM - (1455.3MG/3ML, 3638.25MG/7.5ML, 4851MG/10ML, 7276.5MG/15ML, 14553MG/30ML, 24255MG/50ML, 48510MG/100ML)

<b>Generic Name</b>	GADOPICLENOL	<b>Innovator</b>	GUERBET
<b>Dosage</b>	1455.3MG/3ML, 3638.25MG/7.5ML, 4851MG/10ML, 7276.5MG/15ML, 14553MG/30ML, 24255MG/50ML, 48510MG/100ML	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	None	<b>Known Para IV Filers</b>	None
<b>Other ANDA developers</b>	None	<b>Tentative Approvals</b>	None
<b>Final Approvals</b>	None	<b>Generic Launches</b>	None
<b>Indication</b>	ELUCIREM is a gadolinium-based contrast agent indicated in adult and pediatric patients aged 2 years and older for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in: • the central nervous system (brain, spine, and associated tissues), • the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system).		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events



Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.